Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.70 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | JUN | P05412 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.49 |
| ▸ | VCP | P55072 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11067984 | 1.00 | CYP11B1 (0.70) | CYP11B1CYP11B2RAB9AKMT2AMAPT | |
| SCHEMBL11067983 | 1.00 | CYP11B1 (0.70) | CYP11B1CYP11B2RAB9AKMT2AMAPT | |
| SCHEMBL29419007 | 0.89 | CYP11B1 (0.86) | CYP11B1CYP11B2RAB9AKMT2AMAPT | |
| SCHEMBL28356916 | 0.86 | MAPT (0.81) | CYP11B1CYP11B2RAB9AKMT2AMAPT | |
| SCHEMBL29691639 | 0.85 | CYP11B1 (0.86) | CYP11B1CYP11B2RAB9AKMT2AMAPT | |
| SCHEMBL29691623 | 0.85 | CYP11B1 (0.86) | CYP11B1CYP11B2RAB9AKMT2AMAPT | |
| SCHEMBL31668803 | 0.83 | CYP11B2 (1.00) | CYP11B1CYP11B2RAB9AKMT2AMAPT | |
| SCHEMBL9268248 | 0.83 | CYP11B2 (1.00) | CYP11B1CYP11B2RAB9AKMT2AMAPT | |
| SCHEMBL5496395 | 0.83 | CYP11B2 (1.00) | CYP11B1CYP11B2RAB9AKMT2AMAPT | |
| SCHEMBL29691532 | 0.83 | CYP11B1 (0.82) | CYP11B1CYP11B2RAB9AKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-4490531-A | THROMBOXAN INHIBITOR, ANTITUMOR AGENT, HYPOTENSIVE AGENT | THE UPJOHN COMPANY (US) | 1984-12-25 | — | — | US | disclosed |
| EP-0069521-A2 | Pyridinyl and imidazolyl derivatives of benzofurans and benzothiophenes | THE UPJOHN COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | CYP11B1 993/4885CYP11B2 949/4885RAB9A 2530/4885 |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | HSF1, SIRT1, SIRT2 | CYP11B1 3211/4885CYP11B2 3289/4885RAB9A 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.